Natural Health Trends Corp. Overview
Natural Health Trends Corp. is a micro-cap, Delaware-incorporated, Nasdaq-listed direct-selling and e-commerce company that markets wellness supplements, herbal formulations, skincare and lifestyle products under the NHT Global brand. Its economic engine is a single binary-with-unilevel compensation plan operated through an online ordering platform, with roughly 82–83% of revenue booked by its Hong Kong subsidiary and shipped almost entirely to members residing in mainland China through third-party importers of record. The company owns no manufacturing, carries no financial debt, sources finished goods from contract manufacturers, and historically distributed most of its free cash to shareholders. Revenue has contracted from a 2016 peak of USD 287.7 M to USD 39.8 M in FY2025 and an annualised run-rate near USD 30–36 M in 2026, while the active member base has fallen to 26,000. The investment case now rests on liquidation-like balance-sheet value, cost restructuring and the durability of its China-linked member franchise.
Company's own description (paraphrased from FY2025 10-K)
The company describes itself as an international direct-selling and e-commerce business that, through subsidiaries, sells personal care, wellness and "quality of life" products under the NHT Global brand. Its wholly owned subsidiaries have physical presence in the Americas (United States, Canada, Cayman Islands, Mexico, Peru, Colombia), Greater China (Hong Kong, Taiwan, mainland China), Southeast Asia (Malaysia, Singapore), South Korea, Japan, India and Europe, and it serves Russia and Kazakhstan through a local service provider. Management states that most order volume — especially in Hong Kong — is for personal consumption arising from existing members' referrals, and frames its mission as enriching customers' lives while allowing members to earn from product sales.
Business model
Channel: Network marketing (multi-level marketing) executed almost entirely online. Members order through the company's proprietary web platform and personalised replicating websites; substantially all sales occur via the internet, and members pay by card before shipment, so receivables are minimal (FY2025 10-K).
Compensation plan: A "seamless" global binary plan with unilevel features; each product carries bonus-volume points (a percentage of wholesale price); commissions are paid weekly by the enrolling subsidiary on down-line purchases across all markets. Generation bonuses reach up to three generations on purchases and up to seven generations on commissions in some markets. Commission payouts can be capped weekly in dollar terms or as a percentage of sales. No commission is paid for enrolment itself.
China structure: The company holds no China direct-selling licence. Chinese members buy through the Hong Kong e-commerce direct-selling platform (revenue recognised in Hong Kong; goods delivered to third-party importers of record who pay duties) and/or through a separate China e-commerce retail platform that pays no commissions. A preliminary licence application was withdrawn in 2019 on a Chinese authority's recommendation.
Supply: All products are manufactured by a limited number of third-party contract manufacturers located in the United States, South Korea, Hong Kong, Taiwan, Europe and China. Approximately 40% of the product sourcing base was moved from America to East Asia during 2025 to mitigate tariffs (Q4 2025 release).
Cost structure: Commissions consume ~41% of net sales (41.0% FY2025; 40.9% FY2024); gross margin ~74–75%; SG&A ~37% of sales in FY2025.
Revenue model mix (FY2025 10-K)
| Revenue component (USD K) | FY2024 | FY2025 |
|---|---|---|
| Product sales | 41,729 | 39,017 |
| Administrative fees, freight and other | 1,544 | 1,080 |
| Less: sales returns | -310 | -321 |
| Total net sales | 42,963 | 39,776 |
Product sales therefore represent ~98% of net revenue; there is no subscription, licensing or service revenue of significance. Administrative fees (membership/enrolment-related fees) and freight recovery are the only non-product streams.
Value-chain position, customers and end-markets
NHTC sits at the brand-owner/marketer layer: it designs or co-develops formulations with suppliers, owns private-label trademarks, and controls distribution, compensation and member engagement, while outsourcing manufacturing and much of logistics. Its customers are its "members" — independent contractors who buy for personal consumption, resale, or both — plus "preferred customers" in some markets. No single customer exceeds 10% of sales, but sales concentrate in a few large member networks. End-markets are consumer health supplements (VMS), herbal/TCM-adjacent supplements, skincare and weight-management products, with ≥10% of revenue each from Premium Noni Juice, Triotein™ and the probiotics line (Enhanced Essential Probiotics and Enhanced Biotic Trio).
Independent characterisation
In substance NHTC is a China-consumer health-products marketer operating offshore via Hong Kong, structurally exposed to (i) Chinese regulatory tolerance of cross-border member-driven sales, (ii) Chinese consumer sentiment, and (iii) US–China trade policy (because goods were historically US-made). The model is asset-light and cash-generative only at scale; below ~USD 45 M of revenue the fixed cost base (listing, executive pay, multi-country subsidiaries) has produced operating losses in every year since FY2022. The company has evolved from a growth-oriented MLM into a shrinking, over-capitalised entity whose principal "product" for public shareholders has been capital return — now being curtailed.
Strategy
Stated strategic themes (paraphrased from FY2025 10-K and 2025–2026 earnings calls)
Member success as core objective: The company frames its strategy around helping members achieve health, beauty and financial goals, built on six claimed competencies: culturally aligned field leaders, a disciplined product-launch capability, a comprehensive training ladder, a year-round incentive plan, an easy-entry commission structure, and continuously improving member service.
Cost realignment: "Align costs with global sales performance" to restore profitability (Q3 2025 release).
Supply-chain localisation: Move sourcing closer to Asian demand to reduce tariff exposure and logistics cost.
Digital and AI investment: Refreshed websites, AI-powered member app, AI agents for logistics and service (Q1 2026 call).
Product innovation: New skincare (Soo:vea), weight-management (TwinSlim Coffee/Tomato Soup), digestive (Super Nutri One), anniversary "signature products".
Momentum events: 25th anniversary celebration in Hong Kong (initially targeting ~1,500 attendees per the Feb 2026 release; revised to "more than 1,000" in July 2026) to reconfirm strategy and re-energise members.
Capital return: Commitment to financial discipline, free-cash-flow growth and shareholder returns (Feb 2026 Broady release), operationalised through a reduced dividend and resumed buybacks.
Initiatives in the last 24 months
| Initiative | Date | Target / detail | Status |
|---|---|---|---|
| HQ relocation Hong Kong → California | Feb 2025 | Reduce Hong Kong political/operational concentration | Completed |
| Colombia market entry | 2,025 | New in-country ordering and office | Launched |
| Supply-chain shift to East Asia | 2,025 | ~40% of sourcing moved from America to East Asia by Q4 2025 | Ongoing; gross margin to 75.2% in Q2 2026 |
| Restructuring (workforce optimisation, office downsizing, manufacturing relocation) | Announced Nov 2025 | USD 1.5 M annualised savings; ~USD 250 K one-time charge (actual Q4 2025 charge USD 283 K) | Substantially complete; >USD 600 K saved in H1 2026 |
| Dividend reduction | Effective Q1 2026 | Quarterly dividend cut from USD 0.20 to USD 0.10 | Implemented |
| Broady block repurchase | Feb 2026 | 2,935,227 shares at USD 2.00 (USD 5.9 M); cuts annual dividend outlay by ~USD 1.2 M | Completed |
| Website/brand refresh; AI member app; AI agents | 2,026 | Improve member experience and efficiency | Website launched; app/agents in development |
| Soo:vea skincare launch | Sep 2025 presale | New beauty line in Hong Kong | Launched |
| Super Nutri One | Q1 2026 | Digestion/detox/immunity | Launched |
| 25th anniversary programme | Q3 2026 | Prizes, incentives, signature products | Event held/planned in Q3 2026; results not yet reported |
| Share repurchase resumption | Jul 2026 | USD 15.9 M remaining under programme | Authorised |
Guidance and targets
The company provides no revenue, earnings or medium-term financial targets. The only quantified target is the USD 1.5 M annualised restructuring savings, with most expected in 2026 and the remainder later due to facility timing. No ESG commitments or emissions targets are disclosed.
Products & Services
All products are sold under the NHT Global brand within the Primary Reporting Unit (subsets in China and Russia/Kazakhstan). The company does not publish SKU-level revenue, specifications, or price lists in its filings; pricing is set per market at wholesale/member and retail levels — specific prices not publicly disclosed in filings. Launch years are given only where disclosed.
Wellness (dietary and nutritional supplements — liquids, capsules, tablets, powders)
| Product | Description / function (company category description) | Notes |
|---|---|---|
| Premium Noni Juice | Noni fruit liquid supplement; antioxidant/general wellness | ≥10% of revenue; single-source supplier |
| Triotein™ | Protein/nutritional supplement | ≥10% of revenue; single-source supplier |
| Enhanced Essential Probiotics | Digestive-health probiotic | Part of probiotics line ≥10% of revenue |
| Enhanced Biotic Trio | Pre/pro/postbiotic digestive supplement | Renamed from "Biotic Trio" (FY2024 10-K) |
| Cluster X2™ | Wellness supplement | — |
| Children's Chewable Multivitamin | Paediatric multivitamin | — |
| ReStor Silver™ | Wellness supplement | — |
| Glucosamine 2200™ | Joint-health supplement | — |
| FibeRich™ | Dietary fibre / digestive health | — |
| Energin | Energy support supplement | — |
| Omega-3 Essential Fatty Acids | Heart health | — |
| StemRenu® | Cellular-health supplement | — |
| OcuFocus™ | Vision health | — |
| CurcuMore™ | Curcumin-based supplement | — |
| Ultra B Complex | B-vitamin complex | — |
| CalComplex | Calcium/mineral supplement | — |
| Collagen Supreme | Collagen supplement | — |
| MetaBoost | Metabolic support | — |
| RelaxaPro | Relaxation/sleep support | — |
| Super Nutri One | Digestion, detox and immunity support | Launched in Q1 2026 (Q1 2026 call) |
Herbal (traditional Chinese medicine-inspired)
| Product | Description |
|---|---|
| LivaPro™ | Liver-support herbal supplement |
| Cordyceps Mycelia CS-4™ | Cordyceps-based herbal supplement |
| RespFactor™ | Respiratory-support herbal supplement |
Beauty (facial, hand, body and hair care)
| Product | Notes |
|---|---|
| Skindulgence™ Essence Gel | Hydrating gel |
| Skindulgence® Revitalizing Serum | Anti-ageing serum |
| Skindulgence® Revitalizing Eye Cream | Eye care |
| Floraeda Toner and Primer | Toner/primer |
| Botanical Hand Protector™ | Hand care |
| Micellion Cleansing Water | Cleanser |
| Root Revive Hair Serum | Hair/scalp care |
| Soo:vea Moisturizing Cleanser | New skincare line; presale in Hong Kong at end-September 2025 |
| Soo:vea Moisturizing Toner | Soo:vea line |
| Soo:vea Moisturizing Booster | Soo:vea line |
| Soo:vea Moisturizing Cream | Soo:vea line |
| Beliné Triple Action Day Cream | Listed first in FY2025 10-K |
| Discontinued from FY2025 list | Skindulgence 30 Minute Firming System, BioCell SC Mask, Airelle® serum/repair complex/eye & lip treatment, Color Awakening Lipstick™, Adamas™ Brightening Night Cream, Skindulgence Probiotic Ampoule, Skindulgence Daily Gentle Facial Cleanser (all in FY2024 list only) |
Lifestyle (weight management, vitality)
| Product | Notes |
|---|---|
| Alura Lux™ by NHT Global | Topical gel for intimate wellness/vitality |
| Valura Lux™ | Topical gel (male-oriented counterpart) |
| LaVie+™ | Vitality supplement |
| TwinSlim™ Probiotics | Weight-management probiotic |
| TwinSlim™ Coffee | Weight-management beverage (new in FY2025 list) |
| TwinSlim™ Tomato Soup | Meal-replacement/weight-management (new in FY2025 list) |
| NaturalGlo™ | Beauty-from-within supplement |
At-Home Tests
| Product | Notes |
|---|---|
| BioEssence Wellness Panel | At-home kit measuring 17+ biomarkers across cardiovascular, hormonal, inflammatory, metabolic and nutritional health |
Discontinued categories (present in FY2024 10-K, absent in FY2025)
| Category | Product |
|---|---|
| Home | AquaPur Desktop Water Purifier |
| Daily | Smart Sonic Toothbrush |
Services and platforms
-
Proprietary web-based ordering and commission engine; personalised replicating member websites (www.nhtglobal.com).
-
Oracle E-Business Suite for finance, inventory, purchasing and costing.
-
Enhanced corporate/member website with refreshed branding launched around Q1 2026; an AI-powered member app and AI agents for logistics and member services were reported as under development (GuruFocus summary of Q1 2026 call).
-
Member training, incentive trips, and events (e.g., Asia Forum in Bangkok, January 2025; incentive trip to Paris, October 2024; Jeju training, June 2024).
Financial Narrative
Sources: FY2024 and FY2025 figures from company filings (10-K and 8-K); FY2021–FY2023 from S&P Global Market Intelligence data (StockAnalysis.com), cross-checked against filed 8-K totals for FY2023 (revenue USD 43,924 K; net income USD 568 K).
Income statement
Revenue CAGR FY2021–FY2025: -9.8% per year (USD 60.01 M → USD 39.78 M). Since the FY2016 peak (USD 287.7 M), revenue has fallen ~86%.
Commentary. Three features dominate. First, gross margin has been remarkably stable at 73.5–75.0%, reflecting premium pricing intrinsic to the MLM channel; the 2026 improvement to ~75% stems from relocating manufacturing to East Asia (Q2 2026 release/Quartr). Second, the business crossed into operating loss in FY2022 and has not recovered: commissions (~41%) and SG&A (~37%) together exceed gross margin at current scale. Reported net income in FY2022–FY2024 was positive only because interest and investment income on a large cash pile (other income USD 1.9 M in FY2024) offset operating losses. As cash was returned to shareholders and the Tax Act liability paid, other income fell to USD 1.24 M in FY2025 and USD 0.49 M in H1 2026, exposing the operating loss. Third, FY2025 included USD 283 K of restructuring charges and an unusual USD 175 K Q4 tax expense despite a pre-tax loss (foreign tax), turning the year to a USD 882 K net loss.
Quarterly trajectory
Q1 2025 and Q3 2025 revenue derived arithmetically from reported half-year and full-year totals. Q2 2026 revenue of USD 7.6 M was the lowest quarterly figure in the dataset, down 23% YoY and 17% QoQ, driven by Chinese consumer caution, regulatory uncertainty that caused some members to pause, and member misconduct in Hong Kong.
H1 2026 vs H1 2025 — Q2 2026 8-K
Restructuring savings were ~USD 300 K per quarter in Q1 and Q2 2026 (>USD 600 K year-to-date); SG&A fell 9% YoY in Q2 2026 but rose as a share of the shrinking revenue base.
Balance sheet
30 June 2026 (Q2 2026 8-K): cash USD 9.50 M; marketable securities USD 9.12 M; total assets USD 29.21 M; current liabilities USD 11.94 M; lease liabilities USD 2.75 M; equity USD 15.20 M; working capital USD 11.77 M; treasury stock USD 30.36 M (up from USD 24.40 M after the Broady repurchase); accumulated deficit USD 38.76 M.
Commentary. The company has never used financial leverage in the period reviewed; "debt" in aggregator data consists solely of operating lease liabilities. Net cash fell from USD 80.7 M (FY2021) to USD 26.9 M (FY2025) and roughly USD 15.9 M (June 2026). The drivers are (i) ~USD 9.2 M per year of dividends, (ii) the 2017 Tax Act transition-tax installments (approx. USD 4.0 M in FY2024 and USD 5.1 M in FY2025, implied by the difference between reported operating cash flow and operating cash flow before installments), (iii) operating losses, and (iv) the USD 5.9 M Broady repurchase in Q1 2026. Deferred revenue (USD 4.2 M at June 2026) and eWallet balances (USD 2.6 M) are member-related liabilities that would need funding in a wind-down scenario.
Cash flow
H1 2026: operating cash flow USD -2.16 M; capex USD -0.44 M (largely leasehold/office related given a USD 1.36 M new right-of-use asset); buybacks USD -5.87 M; dividends USD -1.72 M.
Ratios
ROIC is not meaningful: operating income is negative and invested capital excluding cash is negative (member liabilities exceed operating assets). Net debt/EBITDA and interest coverage are not applicable (no financial debt; no interest expense).
Inflection points. FY2022 marked the shift to operating losses as revenue fell 18%; FY2025 marked the shift to net losses as investment income shrank; Q2 2026 marked a renewed acceleration of decline (-23% YoY) just as restructuring savings began to flow.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (USD Mn)
| Segment revenue (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Primary Reporting Unit | 56.91 | 46.56 | 42.21 | 40.89 | 38.39 |
China | 2.24 | 2.02 | 1.24 | 1.58 | 0.95 |
Russia and Kazakhstan | 0.85 | 0.56 | 0.48 | 0.49 | 0.44 |
Total | 60.01 | 49.13 | 43.92 | 42.96 | 39.78 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Primary Reporting Unit YoY growth | -9.3 | -3.1 | -6.1 |
China YoY growth | -38.6 | 27.4 | -39.9 |
Russia and Kazakhstan YoY growth | -14.3 | 2.1 | -9.4 |
Primary Reporting Unit share of revenue | 96.1 | 95.2 | 96.5 |
China share of revenue | 2.8 | 3.7 | 2.4 |
Russia and Kazakhstan share of revenue | 1.1 | 1.1 | 1.1 |
Income Statement
| Metric (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 60.01 | 49.13 | 43.92 | 42.96 | 39.78 |
Cost of sales | 15.01 | 12.66 | 11.17 | 11.18 | 10.52 |
Gross profit | 45.00 | 36.47 | 32.75 | 31.79 | 29.25 |
Commissions expense | — | — | — | 17.57 | 16.30 |
SG&A | — | — | — | 15.51 | 14.76 |
Operating income | 1.57 | -0.27 | -1.67 | -1.30 | -1.81 |
Depreciation & amortization | — | — | — | 0.13 | 0.11 |
EBITDA (operating income + D&A) | — | — | — | -1.17 | -1.70 |
Other income, net | — | — | — | 1.92 | 1.24 |
Pre-tax income | 1.51 | 0.60 | 0.75 | 0.62 | -0.57 |
Income tax provision | — | — | — | 0.05 | 0.32 |
Net income | 1.09 | 0.31 | 0.57 | 0.57 | -0.88 |
Per-share metric (USD)
| Per-share metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPS basic | 0.09 | 0.03 | 0.05 | 0.05 | -0.08 |
EPS diluted | 0.09 | 0.03 | 0.05 | 0.05 | -0.08 |
Dividends per share | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 |
Margin (%)
| Margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 74.98 | 74.23 | 74.56 | 73.98 | 73.54 |
Commissions as % of sales | — | — | 42 | 40.9 | 41.0 |
Operating margin | 2.62 | -0.55 | -3.80 | -3.02 | -4.54 |
EBITDA margin | — | — | — | -2.72 | -4.27 |
Pre-tax margin | 2.52 | 1.23 | 1.70 | 1.44 | -1.43 |
Net margin | 1.81 | 0.64 | 1.29 | 1.33 | -2.22 |
Revenue growth YoY | -3.33 | -18.12 | -10.60 | -2.19 | -7.42 |
Income Statement and Per-Share Data
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|
Net sales (USD K) | 10,846 | 10,737 | 9,813 | 9,477 | 9,749 | 9,206 | 7,603 |
Operating income (USD K) | -421 | -345 | -333 | -495 | -635 | -474 | -643 |
Net income (USD K) | 176 | 122 | 15 | -431 | -588 | -154 | -451 |
Diluted EPS (USD) | 0.02 | 0.01 | 0.00 | -0.04 | -0.05 | -0.02 | -0.05 |
Active members (count) | 30,870 | 30,180 | 29,260 | 28,030 | 26,650 | 26,400 | 26,000 |
Income Statement (Half-Yearly)
| Metric (USD K) | H1 2025 | H1 2026 |
|---|---|---|
Net sales | 20,550 | 16,809 |
Gross profit | 15,160 | 12,624 |
Commissions expense | 8,500 | 6,964 |
SG&A | 7,338 | 6,777 |
Operating loss | -678 | -1,117 |
Other income, net | 813 | 485 |
Net income | 137 | -605 |
Net cash used in operating activities | -5,151 | -2,161 |
Balance Sheet
| Metric (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash & cash equivalents | — | — | — | 13.53 | 6.81 |
Marketable securities | — | — | — | 30.41 | 22.06 |
Cash + marketable securities | 83.84 | 69.67 | 56.18 | 43.94 | 28.87 |
Inventories | — | — | — | 3.27 | 2.05 |
Total current assets | — | — | — | 50.98 | 34.19 |
Total assets | — | — | — | 55.36 | 38.43 |
Total current liabilities | — | — | — | 20.80 | 13.69 |
Income taxes payable (incl. Tax Act liability) | — | — | — | 4.91 | 0.01 |
Deferred revenue | — | — | — | 6.43 | 5.57 |
Amounts held in eWallets | — | — | — | 3.29 | 2.84 |
Financial debt (short-term) | 0 | 0 | 0 | 0 | 0 |
Financial debt (long-term) | 0 | 0 | 0 | 0 | 0 |
Operating lease liabilities (total) | 3.17 | 4.12 | 3.46 | 2.64 | 2.00 |
Net cash (cash + securities − lease liabilities) | 80.68 | 65.54 | 52.71 | 41.30 | 26.87 |
Goodwill & intangibles (separately reported) | — | — | — | 0 | 0 |
Total stockholders' equity | — | — | — | 32.87 | 23.43 |
Working capital | — | — | — | 30.18 | 20.51 |
Cash Flow
| Metric (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | 1.02 | -4.85 | -4.28 | -3.37 | -6.00 |
Operating cash flow before Tax Act installments | — | — | — | 0.60 | -0.94 |
Capital expenditure | -0.23 | -0.14 | -0.05 | -0.06 | -0.07 |
Free cash flow | 0.79 | -5.00 | -4.32 | -3.42 | -6.07 |
Dividends paid | — | — | — | -9.21 | -9.21 |
Share buybacks | — | — | — | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (%) — FY2024 on year-end equity; FY2025 on average equity | 1.7 | -3.1 |
ROA (%) — FY2024 on year-end assets; FY2025 on average assets | 1.0 | -1.9 |
Current ratio (x) | 2.45 | 2.50 |
Lease liabilities / equity (x) | 0.08 | 0.09 |
Asset turnover (x) — FY2025 on average assets | 0.78 | 0.85 |
Inventory days (FY2025 on average inventory) | — | 92 |
Payables days (FY2025 on average payables) | — | 25 |
Cash conversion cycle (days, receivables ≈ 0) | — | 67 |
Markets
| Market (USD K) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong (substantially all shipped to members in China) | 34,898 | 35,106 | 32,671 |
Taiwan | 2,181 | 1,591 | 1,542 |
China (e-commerce retail segment) | 1,240 | 1,580 | 950 |
Russia and Kazakhstan | 480 | 490 | 444 |
Europe | 733 | 635 | 530 |
All other markets (Americas, Japan, South Korea, Malaysia/Singapore, India) | 4,392 | 3,561 | 3,639 |
Total | 43,924 | 42,963 | 39,776 |
Region Margins & Growth (%) and Revenue by Region (%)
| Market metric (%) | FY2024 | FY2025 |
|---|---|---|
Hong Kong YoY growth | 0.6 | -6.9 |
Taiwan YoY growth | -27.1 | -3.1 |
China retail YoY growth | 27.4 | -39.9 |
Russia and Kazakhstan YoY growth | 2.1 | -9.4 |
Europe YoY growth | -13.4 | -16.5 |
All other markets YoY growth | -18.9 | 2.2 |
Hong Kong share of revenue | 81.7 | 82.1 |
Geographic Revenue
| Active members | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong (incl. China residents) | 23,490 | 23,150 | 19,430 |
Americas | 4,040 | 3,360 | 3,460 |
Taiwan | 2,230 | 1,870 | 1,850 |
Europe | 870 | 790 | 640 |
Russia and Kazakhstan | 530 | 600 | 440 |
Japan | 520 | 440 | 340 |
India | 300 | 340 | 210 |
Malaysia and Singapore | 350 | 250 | 220 |
South Korea | 80 | 70 | 60 |
Total | 32,410 | 30,870 | 26,650 |
Share Price & Returns
| Reference point | Price (USD) | Source |
|---|---|---|
31 Dec 2025 close | 3.09 | DEF 14A |
~4 Feb 2026 | ~3.75 | Fintool (Q4 2025 coverage) |
52-week range (as of ~Aug 2026) | 1.50–4.75 | StockAnalysis.com |
29 Jul 2026 intraday (Q2 print) | ~1.58 | MarketBeat |
24 Sep 2026 close | 1.01 | StockAnalysis.com |
Capital Markets Data (USD)
| TSR index (USD 100 at 31 Dec 2022) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Value of USD 100 investment | 194.17 | 179.59 | 151.21 |
Capital Markets
| Metric | NHTC |
|---|---|
Market capitalisation (USD Mn) | 8.7 |
Cash + securities (USD Mn, 30 Jun 2026) | 18.6 |
Enterprise value excl. leases (USD Mn) | -9.9 |
Enterprise value incl. lease liabilities (USD Mn) | -7.2 |
EV/EBITDA | not meaningful (negative EV and EBITDA) |
EV/Sales (TTM revenue USD 36.0 M) | negative |
P/B (book USD 15.2 M; USD 1.77/share) | 0.57 |
Price / net cash per share (~USD 2.17) | 0.47 |
Price/Sales (TTM) | 0.24 |
Dividend per share (USD)
| Dividend per share (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Regular dividends declared | 0.80 | 0.80 | 0.80 | 0.80 | 0.80 |
Analyst Conclusions
Management guidance
No quantitative revenue or earnings guidance. Qualitative outlook (Q2 2026): environment remains challenging in China; additional restructuring savings expected in H2 2026; more aggressive member-support programmes and campaigns; continued investment in products and technology; 25th anniversary to reconfirm strategy.
Consensus
No analyst consensus exists. On simple extrapolation of H1 2026 (USD 16.8 M), FY2026 revenue would land around USD 32–34 M (-15% to -20%), implying a continued operating loss unless H2 savings and anniversary sales outperform — this is an analyst illustration, not a forecast from any source.
Bull case
-
Deep discount to cash: At ~0.47x net cash per share and 0.57x book, with no debt, even a slow wind-down could return more than the market price, and buybacks at these levels are mechanically accretive.
-
Cost base resetting: USD 1.5 M annualised savings (~4% of revenue), gross margin at 75%, and the end of Tax Act payments could bring the business close to cash breakeven on an operating basis.
-
Optionality on China sentiment: A stabilisation in China consumer confidence or US–China trade détente, combined with the anniversary programme, could restore Hong Kong orders, which management described as stable for four quarters before Q2 2026.
Bear case
-
Accelerating revenue decline: Q2 2026 revenue fell 23% YoY and 17% QoQ; active members down 20% since FY2023 — the shrinking base may outrun cost cuts.
-
Value leakage: Fixed corporate costs (executive and director pay ~USD 2.2 M), ongoing operating cash burn (USD 2.2 M in H1 2026) and capital returns could erode the cash cushion before any turnaround, while the new 1.1 M-share equity plan introduces dilution.
-
Binary regulatory/listing risks: Any Chinese enforcement against the cross-border model would impair ~83% of revenue; a sustained sub-USD 1.00 price would trigger Nasdaq deficiency procedures and potential reverse-split or delisting decisions.
Catalysts and monitorables (next 12 months)
-
Q3 2026 results (expected early November 2026): anniversary event impact, Q3 revenue vs Q3 2025 (USD 9.5 M), restructuring savings run-rate.
-
Dividend status: confirmation of any pause/suspension and capital-allocation framework.
-
Pace of open-market buybacks under the USD 15.9 M authorisation.
-
Active member count trajectory (26,000 at June 2026).
-
Any Nasdaq minimum-bid deficiency notice or reverse-split proposal.
-
China regulatory developments and resolution of Hong Kong member misconduct.
-
US–China tariff changes affecting remaining US-sourced products.
-
FY2026 10-K (expected Feb 2027): going-forward risk language on cash flow and dividends.
-
Any strategic-alternatives process or insider buying/selling (executives hold ~10% combined).
Analyst verdict
Natural Health Trends is no longer a growth story or even a stable income story; it is a melting ice cube with a strong balance sheet relative to its equity value. The core facts are stark. Revenue has fallen from USD 60.0 M in FY2021 to a run-rate near USD 32–36 M, the active member base has shrunk 20% since FY2023, and the company has posted operating losses for four consecutive years. Approximately 83% of revenue depends on a cross-border structure into China that operates without a direct-selling licence and that was destabilised again in Q2 2026 by regulatory uncertainty and member misconduct.
Against this, the equity is priced at well under half of net cash. At USD 1.01, the market capitalisation of roughly USD 8.7 M compares with USD 18.6 M of cash and securities and no financial debt at June 2026. That gap reflects rational investor scepticism about whether cash will ever reach shareholders: liabilities to members (deferred revenue, eWallets) must be honoured, operating burn continues, executive compensation is heavy relative to scale, and governance is insular, with long-tenured and consultant-linked directors and no activist or large outside holder after the Broady exit.
The restructuring is real but modest relative to the revenue slide, and the anniversary programme is a one-off stimulus. The decisive variables over the next 12 months are whether management prioritises returning cash — through disciplined buybacks below net cash or a more formal capital-return plan — over funding losses, and whether Hong Kong/China order volumes stabilise after the Q2 shock.
Verdict: Fundamentally negative on the operating business; the shares screen as a deep-value, net-cash special situation whose outcome hinges on capital allocation and governance rather than growth. Absent evidence of stabilising member counts or a clearer capital-return commitment, the risk of value leakage outweighs the apparent discount.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Age | Tenure | Prior roles | Education |
|---|---|---|---|---|---|
Chris T. Sharng | President (principal executive officer); Director | 62 | President since Feb 2007; director since Mar 2012; joined Aug 2004 as EVP & CFO | CFO, NorthPole Limited (2004); SVP & CFO, Ultrak Inc./American Building Control (2000–2004); Mattel, Inc., latterly VP International Finance (1989–2000) | MBA, Columbia University; bachelor's, National Taiwan University |
Timothy S. Davidson (referred to as "Scott Davidson" in earnings releases) | CFO, SVP and Corporate Secretary | 55 | CFO since Feb 2007; CAO 2004–2007; Secretary since Jan 2014 | Corporate Controller, Celion Networks; Manager of Financial Reporting, IP Communications; Audit Manager, Arthur Andersen | Master's in professional accounting, University of Texas at Austin; bachelor's, East Texas A&M University |
Directors' Remuneration
| Executive / year | Salary | Bonus | Stock awards (phantom shares) | All other | Total |
|---|---|---|---|---|---|
Sharng FY2025 | 1,000,000 | 0 | 171,607 | 15,750 | 1,187,357 |
Sharng FY2024 | 1,000,000 | 0 | 275,767 | 15,525 | 1,291,292 |
Davidson FY2025 | 400,000 | 0 | 57,444 | 23,030 | 480,474 |
Davidson FY2024 | 400,000 | 0 | 92,290 | 27,513 | 519,803 |
Board of Directors
| Director | Age | Role | Since | Independent | Background |
|---|---|---|---|---|---|
Randall A. Mason | 67 | Chairman; Audit Committee Chair | Director May 2003; Chair Mar 2006 | Yes | Founder/CEO of Marden Rehabilitation Associates (since 1989); BS chemical engineering, University of Pittsburgh |
Chris T. Sharng | 62 | Director; President | Mar 2012 | No | See above |
Ching C. Wong | 67 | Director; Nominating & Governance Chair (pre-meeting) | Jun 2020 | Yes | Consultant to company 2016–2020; employee 2004–07 and 2009–10; ex-Corporate Controller, North Pole Ltd; PhD Marketing Management (SUFE), law degree (Tsinghua); FCCA |
Ellen Sun | 57 | Director (Audit, Comp, Nominating committees) | May 2026 | Yes (board determination) | CFO & CCO, Marquest Asset Management; ex-CPP Investment Board; consultant to NHTC Oct 2018–Mar 2026; former controller of NHTC's Taiwan subsidiary; CPA (US), CPA (Canada) |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Renaissance Technologies LLC (13F, Feb 2026) | 581,415 | 6.8 |
Chris T. Sharng | 443,323 | 5.2 |
Timothy S. Davidson | 391,100 | 4.6 |
Randall A. Mason (incl. 23,899 via Marden Rehabilitation) | 252,733 | 2.9 |
Lucy N. Nduati | 18,935 | 0.2 |
All officers, directors & nominees (7 persons) | 1,106,091 | 12.9 |
Competitive Landscape
Key Competitors
| Competitor | Type | Segment overlap | Latest revenue (verified) | Relative positioning |
|---|---|---|---|---|
Herbalife Ltd. (HLF) | Global MLM, nutrition | Weight management, supplements, China | FY2025 net sales ~USD 5.0 B (+ ~6% in Q4 2025) | ~125x NHTC's revenue; scale leader |
Nu Skin Enterprises (NUS) | Global MLM, beauty & wellness | Skincare, supplements, Greater China | FY2025 revenue USD 1.49 B (-14.3%) | Premium beauty/wellness; also shrinking |
USANA Health Sciences (USNA) | Global MLM, nutrition | Supplements, Greater China | FY2025 net sales USD 925.3 M (+8%) | Strong China franchise via licensed BabyCare |
Amway | Private global MLM | Supplements, beauty; licensed in China | — | Largest licensed China direct seller (industry context) |
Infinitus (LKK Health Products) | Private China-licensed direct seller | TCM/herbal health products | — | Direct herbal overlap with LivaPro/Cordyceps |
Perfect (China) | Private China-licensed direct seller | Supplements, personal care | — | Mainland incumbent |
Tiens Group | Private China-based direct seller | Supplements | — | Mainland incumbent |
Jeunesse Global | Private MLM | Anti-ageing skincare, supplements, Asia | — | Asia-heavy peer |
Mannatech (MTEX) | Public small-cap MLM | Supplements, Asia exposure | — | Closest US-listed micro-cap analogue |
LifeVantage (LFVN) | Public small-cap MLM | Supplements, Japan/Asia | — | Small-cap analogue |
Private HK/Taiwan/China small MLMs (unnamed) | Private | Same member pool | — | Company's stated closest competitors |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | NHTC | Herbalife | Nu Skin | USANA |
|---|---|---|---|---|
Revenue (USD Mn) | 39.8 | 5,000 | 1,490 | 925.3 |
Revenue growth (%) | -7.4 | — | -14.3 | 8.0 |
Gross margin (%) | 73.5 | — | — | — |
Operating margin (%) | -4.5 | — | — | — |
Recent Developments
No litigation, regulatory enforcement actions, layoffs with headcount figures beyond the restructuring, or guidance revisions were disclosed in this window.



